Research that was carried out by Baylor College of Medicine and Texas Children's Hospital doctors has led to the U.S. Food ...

WORCESTER, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company ...

CBL-514 is the first and only drug to receive EMA Orphan Drug Designation for Dercum's disease treatment. - CBL-514 received both FDA Orphan Drug Designation and Fast Track designation for Dercum's ...

By converting immunologically 'cold' tumours into 'hot' ones, MB-108 may enhance the efficacy of the MB-101 CAR-T cell ...

Zura Bio (ZURA) “announced the submission of a protocol to its open Investigational New Drug application with the U.S. Food and Drug ...

“We are pleased to have been granted orphan drug designation by the U.S. FDA for AT-02 in ATTR amyloidosis,” said Gregory Bell, M.D., Chief Medical Officer at Attralus. “Current approved therapies for ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

MB-108 shows activity and is well tolerated in recurrent glioblastoma, with preclinical data supporting its combination with ...

The Food and Drug Administration (FDA) has granted Orphan Drug designation to AT-02 for the treatment of transthyretin-associated amyloidosis (ATTR). AT-02 is a fusion protein of humanized ...

Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety with adjusted dosing.

Orphan drugs are further classified as approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) or ...

CBL-514 is the first and only drug to receive EMA Orphan Drug Designation for Dercum's disease treatment. - CBL-514 received both FDA Orphan Drug Designation and Fast Track designation for Dercum ...